Sildenafil Use and Increased Risk of Incident Melanoma in US Men: A Prospective Cohort Study | Dermatology | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.204.227.34. Please contact the publisher to request reinstatement.
1.
Gray-Schopfer  V, Wellbrock  C, Marais  R.  Melanoma biology and new targeted therapy.  Nature. 2007;445(7130):851-857.PubMedGoogle ScholarCrossref
2.
Thompson  JF, Scolyer  RA, Kefford  RF.  Cutaneous melanoma.  Lancet. 2005;365(9460):687-701.PubMedGoogle ScholarCrossref
3.
Siegel  R, Naishadham  D, Jemal  A.  Cancer statistics, 2012.  CA Cancer J Clin. 2012;62(1):10-29.PubMedGoogle ScholarCrossref
4.
Goydos  JS, Mann  B, Kim  HJ,  et al.  Detection of B-RAF and N-RAS mutations in human melanoma.  J Am Coll Surg. 2005;200(3):362-370.PubMedGoogle ScholarCrossref
5.
Davies  H, Bignell  GR, Cox  C,  et al.  Mutations of the BRAF gene in human cancer.  Nature. 2002;417(6892):949-954.PubMedGoogle ScholarCrossref
6.
Hauschild  A, Grob  JJ, Demidov  LV,  et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.  Lancet. 2012;380(9839):358-365.PubMedGoogle ScholarCrossref
7.
Bollag  G, Tsai  J, Zhang  J,  et al.  Vemurafenib: the first drug approved for BRAF-mutant cancer.  Nat Rev Drug Discov. 2012;11(11):873-886.PubMedGoogle ScholarCrossref
8.
Arozarena  I, Sanchez-Laorden  B, Packer  L,  et al.  Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A.  Cancer Cell. 2011;19(1):45-57.PubMedGoogle ScholarCrossref
9.
Packer  LM, East  P, Reis-Filho  JS, Marais  R.  Identification of direct transcriptional targets of V600EBRAF/MEK signalling in melanoma.  Pigment Cell Melanoma Res. 2009;22(6):785-798.PubMedGoogle ScholarCrossref
10.
Dhomen  N, Reis-Filho  JS, da Rocha Dias  S,  et al.  Oncogenic Braf induces melanocyte senescence and melanoma in mice.  Cancer Cell. 2009;15(4):294-303.PubMedGoogle ScholarCrossref
11.
Houslay  MD.  Hard times for oncogenic BRAF-expressing melanoma cells.  Cancer Cell. 2011;19(1):3-4.PubMedGoogle ScholarCrossref
12.
Palit  V, Eardley  I.  An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction.  Nat Rev Urol. 2010;7(11):603-609.PubMedGoogle ScholarCrossref
13.
Ghofrani  HA, Osterloh  IH, Grimminger  F.  Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.  Nat Rev Drug Discov. 2006;5(8):689-702.PubMedGoogle ScholarCrossref
14.
Zhang  X, Yan  G, Ji  J,  et al.  PDE5 inhibitor promotes melanin synthesis through the PKG pathway in B16 melanoma cells.  J Cell Biochem. 2012;113(8):2738-2743.PubMedGoogle ScholarCrossref
15.
Noonan  FP, Zaidi  MR, Wolnicka-Glubisz  A,  et al.  Melanoma induction by ultraviolet A but not ultraviolet B radiation requires melanin pigment.  Nat Commun. 2012;3:884.PubMedGoogle ScholarCrossref
16.
Mitra  D, Robinson  KC, Fisher  DE.  Melanoma and Viagra: an unexpected connection.  Pigment Cell Melanoma Res. 2011;24(1):16-18.PubMedGoogle ScholarCrossref
17.
Madan  V, Lear  JT, Szeimies  RM.  Non-melanoma skin cancer.  Lancet. 2010;375(9715):673-685.PubMedGoogle ScholarCrossref
18.
Bacon  CG, Mittleman  MA, Kawachi  I, Giovannucci  E, Glasser  DB, Rimm  EB.  Sexual function in men older than 50 years of age: results from the health professionals follow-up study.  Ann Intern Med. 2003;139(3):161-168.PubMedGoogle ScholarCrossref
19.
Gao  X, Schwarzschild  MA, O’Reilly  EJ, Wang  H, Ascherio  A.  Restless legs syndrome and erectile dysfunction.  Sleep. 2010;33(1):75-79.PubMedGoogle Scholar
20.
Cho  E, Rosner  BA, Feskanich  D, Colditz  GA.  Risk factors and individual probabilities of melanoma for whites.  J Clin Oncol. 2005;23(12):2669-2675.PubMedGoogle ScholarCrossref
21.
Han  J, Colditz  GA, Hunter  DJ.  Risk factors for skin cancers: a nested case-control study within the Nurses’ Health Study.  Int J Epidemiol. 2006;35(6):1514-1521.PubMedGoogle ScholarCrossref
22.
Walls  AC, Han  J, Li  T, Qureshi  AA.  Host risk factors, ultraviolet index of residence, and incident malignant melanoma in situ among US women and men.  Am J Epidemiol. 2013;177(9):997-1005. doi:10.1093/aje/kws335.Google ScholarCrossref
23.
Sergentanis  TN, Antoniadis  AG, Gogas  HJ,  et al.  Obesity and risk of malignant melanoma: a meta-analysis of cohort and case-control studies.  Eur J Cancer. 2013;49(3):642-657.PubMedGoogle ScholarCrossref
24.
Song  F, Qureshi  AA, Gao  X, Li  T, Han  J.  Smoking and risk of skin cancer: a prospective analysis and a meta-analysis.  Int J Epidemiol. 2012;41(6):1694-1705.PubMedGoogle ScholarCrossref
25.
Colditz  GA, Martin  P, Stampfer  MJ,  et al.  Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women.  Am J Epidemiol. 1986;123(5):894-900.PubMedGoogle Scholar
26.
Hunter  DJ, Colditz  GA, Stampfer  MJ, Rosner  B, Willett  WC, Speizer  FE.  Diet and risk of basal cell carcinoma of the skin in a prospective cohort of women.  Ann Epidemiol. 1992;2(3):231-239.PubMedGoogle ScholarCrossref
27.
Sun  GW, Shook  TL, Kay  GL.  Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis.  J Clin Epidemiol. 1996;49(8):907-916.PubMedGoogle ScholarCrossref
28.
Azzouni  F, Abu samra  K.  Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? a critical analysis and review of the literature.  J Sex Med. 2011;8(10):2894-2903.PubMedGoogle ScholarCrossref
29.
Adamo  CM, Dai  DF, Percival  JM,  et al.  Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy.  Proc Natl Acad Sci U S A. 2010;107(44):19079-19083.PubMedGoogle ScholarCrossref
30.
Das  A, Durrant  D, Mitchell  C,  et al.  Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction.  Proc Natl Acad Sci U S A. 2010;107(42):18202-18207.PubMedGoogle ScholarCrossref
31.
Francis  SH, Busch  JL, Corbin  JD, Sibley  D.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.  Pharmacol Rev. 2010;62(3):525-563.PubMedGoogle ScholarCrossref
32.
Khan  AS, Sheikh  Z, Khan  S, Dwivedi  R, Benjamin  E.  Viagra deafness—sensorineural hearing loss and phosphodiesterase-5 inhibitors.  Laryngoscope. 2011;121(5):1049-1054.PubMedGoogle ScholarCrossref
33.
Guo  D, Tan  YC, Wang  D,  et al.  A Rac-cGMP signaling pathway.  Cell. 2007;128(2):341-355.PubMedGoogle ScholarCrossref
34.
Calvo  F, Sahai  E.  Cell communication networks in cancer invasion.  Curr Opin Cell Biol. 2011;23(5):621-629.PubMedGoogle ScholarCrossref
35.
Malumbres  M, Barbacid  M.  RAS oncogenes: the first 30 years.  Nat Rev Cancer. 2003;3(6):459-465.PubMedGoogle ScholarCrossref
36.
Hoek  KS, Eichhoff  OM, Schlegel  NC,  et al.  In vivo switching of human melanoma cells between proliferative and invasive states.  Cancer Res. 2008;68(3):650-656.PubMedGoogle ScholarCrossref
37.
Miller  AJ, Mihm  MC  Jr.  Melanoma.  N Engl J Med. 2006;355(1):51-65.PubMedGoogle ScholarCrossref
38.
Hacker  E, Hayward  NK, Dumenil  T, James  MR, Whiteman  DC.  The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population.  J Invest Dermatol. 2010;130(1):241-248.PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    2 Comments for this article
    EXPAND ALL
    Melatonin and vitamin D prophylaxis versus melanoma?
    David L. Keller, MD, FACP | Independent Commentator
    The results of this study may be particularly worrisome to men who have used sildenafil and may be at elevated risk of melanoma due to history of extensive sun exposure, basal or squamous cell skin cancers, family history and Parkinson disease (which causes autonomic erectile dysfunction and is associated with elevated risk of melanoma). The April 2014 Mayo Clinic Proceedings contains an editorial advocating adjuvant therapy with vitamin D and melatonin for every stage of melanoma, and as secondary prophylaxis. Given the low risk of harm from these supplements, might it be reasonable for persons at high risk for melanoma to consider taking them as primary prophylaxis? An example might be a man with Parkinson disease-associated sildenafil use, a FH of melanoma, and personal history of sun exposure and basal cell carcinomas.
    CONFLICT OF INTEREST: None Reported
    READ MORE
    Parkinson disease is associated with melanoma & erectile dysfunction
    David L. Keller, M.D. | Independent Commentator
    Parkinson disease (PD) is associated with increased risk of melanoma. PD also causes autonomic neuropathy, often resulting in erectile dysfunction. This study has found an increased risk of melanoma among users of sildenafil, a treatment for erectile dysfunction, and the authors describe a plausible biological mechanism for this possible medication side effect. This may indicate that males with PD should exercise caution with regard to the use of medications such as Viagra, and especially with regard to similar medications such as Cialis Daily, a related phosphodiesterase inhibitor which is approved for daily use as a dual treatment for both erectile dysfunction and symptoms of prostate hypertrophy.
    CONFLICT OF INTEREST: None Reported
    READ MORE
    Original Investigation
    June 2014

    Sildenafil Use and Increased Risk of Incident Melanoma in US Men: A Prospective Cohort Study

    Author Affiliations
    • 1Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
    • 2Department of Dermatology, Rhode Island Hospital, Warren Alpert Medical School, Brown University, Providence
    • 3Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
    • 4Department of Dermatology, Massachusetts General Hospital, Boston
    • 5Graduate Program in Biological and Biomedical Sciences, Harvard Medical School, Boston, Massachusetts
    • 6Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts
    • 7Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis
    • 8Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis
    • 9Department of Epidemiology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
    JAMA Intern Med. 2014;174(6):964-970. doi:10.1001/jamainternmed.2014.594
    Abstract

    Importance  The RAS/RAF/mitogen-activated protein kinase and extracellular signal–regulated kinase (ERK) kinase/ERK cascade plays a crucial role in melanoma cell proliferation and survival. Sildenafil citrate (Viagra) is a phosphodiesterase (PDE) 5A inhibitor commonly used for erectile dysfunction. Recent studies have shown that BRAF activation down-regulates PDE5A levels, and low PDE5A expression by BRAF activation or sildenafil use increases the invasiveness of melanoma cells, which raises the possible adverse effect of sildenafil use on melanoma risk.

    Objective  To evaluate the association between sildenafil use and risk of incident melanoma among men in the United States.

    Design, Setting, and Participants  Our study is a prospective cohort study. In 2000, participants in the Health Professionals’ Follow-up Study were questioned regarding sildenafil use for erectile dysfunction. Participants who reported cancers at baseline were excluded. A total of 25 848 men remained in the analysis.

    Main Outcomes and Measures  The incidence of skin cancers, including melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC), was obtained in the self-reported questionnaires biennially. The diagnosis of melanoma and SCC was pathologically confirmed.

    Results  We identified 142 melanoma, 580 SCC, and 3030 BCC cases during follow-up (2000-2010). Recent sildenafil use at baseline was significantly associated with an increased risk of subsequent melanoma with a multivariate-adjusted hazard ratio (HR) of 1.84 (95% CI, 1.04-3.22). In contrast, we did not observe an increase in risk of SCC (HR, 0.84; 95% CI, 0.59-1.20) or BCC (1.08; 0.93-1.25) associated with sildenafil use. Moreover, erectile function itself was not associated with an altered risk of melanoma. Ever use of sildenafil was also associated with a higher risk of melanoma (HR, 1.92; 95% CI, 1.14-3.22). A secondary analysis excluding those reporting major chronic diseases at baseline did not appreciably change the findings; the HR of melanoma was 2.24 (95% CI, 1.05-4.78) for sildenafil use at baseline and 2.77 (1.32-5.85) for ever use.

    Conclusions and Relevance  Sildenafil use may be associated with an increased risk of developing melanoma. Although this study is insufficient to alter clinical recommendations, we support a need for continued investigation of this association.

    ×